Prevalence of reduced fibronogen binding to platelets in a population of Thoroughbreds

American Journal of Veterinary Research

Volumn 68, Issue 7, 2007, Pages 716-721

  Norris, Jeffrey W ^a   Pratt, Suzanne M ^b   Hunter, Jessica F ^a   Gardner, Ian A ^a   Tablin, Fern ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CITRATE DEXTROSE; ADENINE; ALPHA2BBETA3 INTEGRIN; FIBRINOGEN; INTEGRIN; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BLEEDING DISORDER; BLOOD SAMPLING; BREEDING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GENETIC VARIABILITY; GLANZMANN DISEASE; HORSE; MALE; NONHUMAN; PROTEIN BINDING; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; ANIMAL; ANIMAL DISEASE; BLOOD; HORSE DISEASE; METABOLISM; PREVALENCE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER;

ANIMALIA; EQUIDAE;

ANIMALS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HORSE DISEASES; HORSES; MALE; PLATELET ACTIVATION; PREVALENCE; THROMBIN;

EID: 34547411381     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.7.716     Document Type: Article

References (24)

1. Sutherland RJ, Cambridge H, Bolton JR. Functional and morphological studies on blood platelets in a thrombasthenic horse. Aust Vet J 1989;66:366-370.
2. Christopherson PW, Insalaco TA, van Santen VL, et al. Characterization of the cDNA encoding alphaIIb and beta3 in normal horses and two horses with Glanzmann thrombasthenia. Vet Pathol 2006;43:78-82.
3. Livesey L, Christopherson P, Hammond A, et al. Platelet dysfunction (Glanzmann's thrombasthenia) in horses. J Vet Intern Med 2005;19:917-919.
4. Fry MM, Walker NJ, Blevins GM, et al. Platelet function defect in a thoroughbred filly. J Vet Intern Med 2005;19:359-362.
5. Norris J, Pratt S, Auh J-H, et al. Investigation of a novel, heritable bleeding diathesis of Thoroughbred horses and development of a screening assay. J Vet Intern Med 2006;20:1450-1456.
6. Faraday N, Goldschmidt-Clermont P, Dise K, et al. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994;123:728-740.
7. Bland M. An introduction to medical statistics. 3rd ed. Oxford, England: Oxford University Press, 2002;279-281.
8. Department of Health and Human Services. Summary report. In: National Heart and Lung Institute blood resource studies. Vol 3. Washington, DC: US Government Printing Office, 1972;39-80.
9. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-294.
10. Rodeghiero F. von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002;8:292-300.
11. Castaman G, Fedenci AB, Rodeghiero F, et al. von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003;88:94-108.
12. Michiels JJ, Gadisseur A, Budde U, et al. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost 2005;31:577-601.
13. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol 1974; 28:253-260.
14. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977;60:535-545.
15. Phillips DR, Jenkins CS, Luscher EF, et al. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature 1975;257:599-600.
16. Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001;98:257-265.
17. Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984;74:1221-1228.
18. Woulfe D, Jiang H, Morgans A, et al. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 2004;113:441-450.
19. Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. J Biol Chem 2000;275:27790-27798.
20. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001;292:1728-1731.
21. Chen J, De S, Damron DS, et al. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood 2004;104:1703-1710.
22. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-2208.
23. Cho H, Thorvaldsen JL, Chu Q, et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001;276:38349-38352.
24. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 1996;15:6541-6551.